First Trust Direct Indexing L.P. Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

First Trust Direct Indexing L.P. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,381 shares of the biopharmaceutical company’s stock after purchasing an additional 97 shares during the period. First Trust Direct Indexing L.P.’s holdings in Regeneron Pharmaceuticals were worth $3,254,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of REGN. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the last quarter. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $31,000. MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares during the last quarter. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $37,000. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $40,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 63,208 shares of company stock valued at $62,514,142. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Down 2.0 %

Shares of Regeneron Pharmaceuticals stock traded down $20.57 during midday trading on Thursday, hitting $1,024.09. The company had a trading volume of 378,341 shares, compared to its average volume of 459,242. Regeneron Pharmaceuticals, Inc. has a 52-week low of $688.52 and a 52-week high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a market capitalization of $112.84 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.16 and a beta of 0.13. The company has a 50 day moving average of $992.50 and a 200 day moving average of $954.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on REGN shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective for the company. Argus raised their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, June 24th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,027.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.